INVIVO THERAPEUTICS

Codice
nviv
Risorse esterne
Opinione della community
Prezzo Variazione Volume
2.075 -1.19 €
(-36.45%)
71920
P/E Obiettivo ad 1anno
0 14.63 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 31
Sell : 6

ghed LucaMazzu91 parcall Simone Bonzanini

Commenti


Notizie

Trading Center: Following Shares of InVivo Therapeutics Holdings Corp (NVIV) - Providence Standard

Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. InVivo Therapeutics Holdings Corp (NVIV) has a ...altro » Leggi

A Look Ahead For 2 Stocks: Navigator Holdings Ltd. (NVGS), InVivo Therapeutics Holdings Corp. (NVIV) - Post Analyst

Turning to InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), its shares were trading at $2 a retreat of $-0.1, on the trading floor. The stock, after opening at $2.05, touched a high of $2.1 before paring much of its gains. So far, analysts are ... Leggi

Earnings And Analyst Opinion Offer Spending Insights: InVivo Therapeutics Holdings Corp. (NVIV), Dynegy Inc. (DYN) - Post Analyst

Analysts have placed a $14.63 price target on InVivo Therapeutics Holdings Corp., suggesting a 631.5% gain from recent close. It's currently trading about -74.81% below its 52-week high. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Intraday View. Leggi

Trading Patterns In Focus: InVivo Therapeutics Holdings Corp. (NVIV), Abeona Therapeutics Inc. (ABEO) - Post Analyst

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) traded at an unexpectedly low level on 05/19/2017 when the stock experienced a -4.44% loss to a closing price of $2.15. The company saw 0.25 million shares trade hands over the course of the day. Leggi

Knuckling Down on Shares of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) - Morgan Research

Smart investors are constantly on the lookout for a bargain when it comes to stock picking. As of late, investors have been taking a second look at shares of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV). During recent trading, shares saw a move of ...altro » Leggi

InVivo Therapeutics Holdings Corp. (NVIV) Settles Into New 52-Week Low on May 23 Session - Equities.com

InVivo Therapeutics Holdings Corp. saw 365,429 shares of its stock trade hands, that's out of 32.15 million shares outstand. The stock has an average daily volume of 221,590 shares. After hitting a new 52-week low, InVivo Therapeutics Holdings Corp ... Leggi

Home Analyst Research Hot Stocks Among Investors: US Foods Holding Corp. (USFD), InVivo Therapeutics Holdings... - Post Analyst

Turning to InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), its shares were trading at $2.05 a retreat of $-0.1, on the trading floor. The stock, after opening at $2.15, touched a high of $2.2 before paring much of its gains. So far, analysts are ...altro » Leggi

Option Trading: InVivo Therapeutics Holdings Corp. Winning Long Put Spreads Can Outperform Earnings - CML News

There is a lot less 'luck' involved in successful option trading than many people have come to understand. We can get specific with long put spreads on NVIV in this dossier. Let's look at a two-year back-test of a long put spread strategy and use the ...altro » Leggi

InVivo Therapeutics Holdings Corp. (NVIV) Plunges 9.8% on May 16 - Equities.com

InVivo Therapeutics Holdings Corp. (NVIV) had a rough trading day for Tuesday May 16 as shares tumbled 9.8%, or a loss of $-0.25 per share, to close at $2.30. After opening the day at $2.55, shares of InVivo Therapeutics Holdings Corp. traded as high ... Leggi

Analyst Recommendations And Earnings Forecast: Almaden Minerals Ltd. (AAU), InVivo Therapeutics Holdings Corp ... - Post Analyst

Turning to InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), its shares were trading at $2.25 a retreat of $-0.05, on the trading floor. The stock, after opening at $2.35, touched a high of $2.35 before paring much of its gains. So far, analysts are ... Leggi